Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol,levonorgestrel -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: povidone; lactose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: maize starch; gelatin; magnesium stearate; hypromellose; macrogol 4000; titanium dioxide; iron oxide red; lactose monohydrate - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; gelatin; maize starch; macrogol 4000; magnesium stearate; hypromellose; lactose monohydrate - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: gelatin; macrogol 4000; magnesium stearate; maize starch; lactose monohydrate; titanium dioxide; hypromellose - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: gelatin; hypromellose; iron oxide yellow; titanium dioxide; magnesium stearate; lactose monohydrate; maize starch; macrogol 4000 - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 20 microgram; levonorgestrel, quantity: 100 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 1500; magnesium stearate; microcrystalline cellulose; glycol montanate; polacrilin potassium; titanium dioxide; hypromellose; hyprolose; macrogol 400 - 1. the prevention of pregnancy. 2. the treatment of moderate acne vulgaris not controlled with topical preparations in post-menarchal, pre-menopausal women who accept contraception.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

gilead sciences malaysia sdn. bhd. - emtricitabine; tenofovir alafenamide fumarate; elvitegravir; cobicistat on silicon dioxide -

Israel - English - Ministry of Health

gilead sciences israel ltd - cobicistate; elvitegravir; emtricitabine; tenofovir alafenamide - film coated tablets - tenofovir alafenamide 10 mg; emtricitabine 200 mg; cobicistate 150 mg; elvitegravir 150 mg - emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat - gendevra is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows:• in adults and adolescents aged from 12 years and with body weight at least 35 kg• in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.תוספת התוויה: 2/7/2019addition of new info to posology section: precaution in pregnant women

Israel - English - Ministry of Health

gilead sciences israel ltd - cobicistate; elvitegravir; emtricitabine; tenofovir alafenamide - film coated tablets - tenofovir alafenamide 10 mg; emtricitabine 200 mg; cobicistate 150 mg; elvitegravir 150 mg - emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat - gendevra is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows:• in adults and adolescents aged from 12 years and with body weight at least 35 kg• in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.תוספת התוויה: 2/7/2019addition of new info to posology section: precaution in pregnant women